Form 4: Rigel Pharmaceuticals Director Receives Equity Awards, Reflecting Compensation and Alignment

Rigel Pharmaceuticals Inc. Director Alison L. Hannah was granted 2,500 Restricted Stock Units and 3,000 stock options as part of her compensation, aligning her interests with shareholders.

Summary

• Alison L. Hannah, a Director of Rigel Pharmaceuticals Inc. (RIGL), reported changes in her beneficial ownership of company securities.
• On May 23, 2025, Ms. Hannah was granted 2,500 shares of Common Stock through a Restricted Stock Unit (RSU) award, with a transaction price of $0.
• These RSUs are set to fully vest on the date prior to the Company's next Annual Meeting, contingent on her continuous service on the Board of Directors.
• Additionally, on May 23, 2025, Ms. Hannah was granted 3,000 stock options with an exercise price of $18.95.
• These stock options will vest monthly over one year from the grant date, also subject to her continuous service on the Board.
• The reported beneficial ownership of 10,625 common shares has been adjusted to reflect a one-for-ten reverse stock split that became effective on June 27, 2024.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity awards align the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation filing, not indicative of significant operational news.

Positives

• The granting of equity awards to a director, such as RSUs and stock options, helps align the director's financial interests with those of the company's shareholders, encouraging long-term value creation.
• The awards are part of standard compensation practices for board members, indicating ongoing commitment and incentivization for leadership.

Risks

• The value of the granted equity awards (RSUs and stock options) is subject to the future performance of Rigel Pharmaceuticals' stock price, meaning their ultimate value could be lower than anticipated if the stock declines.
• Vesting of both RSUs and stock options is contingent on the director's continuous service on the Board of Directors, meaning forfeiture could occur if service ceases prematurely.

Future Outlook

The document primarily details past and current equity grants and does not provide forward-looking statements regarding the company's financial performance or strategic outlook, beyond the vesting schedules of the granted awards.

Management Comments

• The filing was signed by Raymond Furey as Attorney-in-Fact for Alison L. Hannah.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, reporting changes in beneficial ownership by insiders. The granting of equity awards like RSUs and stock options is a common practice in the biotechnology and pharmaceutical industry to compensate and incentivize directors and executives, aligning their interests with long-term company performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards granted to the director are intended to align her interests with those of the shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The Restricted Stock Units are expected to fully vest on the date prior to the Company's next Annual Meeting, subject to continuous service.
• The stock options are expected to vest monthly over one year from the grant date, subject to continuous service.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Beneficial Ownership, Equity Awards, Restricted Stock Units, Stock Options, Director Compensation, RIGEL PHARMACEUTICALS INC, RIGL, Corporate Governance